Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 10/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 10/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.77 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 2/20 | 0.57 |
| ▸ | CA2 | P00918 | 2/20 | 0.57 |
| ▸ | CA9 | Q16790 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.54 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14129854 | 0.87 | CYP2D6 (1.00) | CYP2D6CYP2C9CYP3A4CYP1A2CYP2C19 | |
| SCHEMBL2608837 | 0.82 | CYP2D6 (0.66) | CYP2D6CYP2C9CYP3A4CYP1A2CYP2C19 | |
| SCHEMBL12250979 | 0.82 | CYP2D6 (0.66) | CYP2D6CYP2C9CYP3A4CYP1A2CYP2C19 | |
| SCHEMBL7068561 | 0.82 | CYP2D6 (0.77) | CYP2D6CYP2C9CYP3A4CYP1A2CYP2C19 | |
| SCHEMBL28260351 | 0.81 | CYP2D6 (0.76) | CYP2D6CYP2C9CYP3A4CYP1A2CYP2C19 | |
| SCHEMBL285074 | 0.80 | CYP11B1 (0.73) | CYP2D6CYP2C9CYP3A4CYP1A2CYP2C19 | |
| SCHEMBL6573617 | 0.80 | CYP2D6 (0.72) | CYP2D6CYP2C9CYP3A4CYP1A2CYP2C19 | |
| SCHEMBL9451421 | 0.80 | CYP2D6 (0.72) | CYP2D6CYP2C9CYP3A4CYP1A2CYP2C19 | |
| SCHEMBL9471631 | 0.80 | CYP2D6 (0.77) | CYP2D6CYP2C9CYP3A4CYP1A2CYP2C19 | |
| SCHEMBL5202195 | 0.80 | CYP2D6 (0.72) | CYP2D6CYP2C9CYP3A4CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1999009845-A1 | IMIDAZOQUINOXALINE PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-03-04 | — | — | WO | claimed |
| EP-0028410-B1 | USE OF THROMBOXANE-SYNTHETASE INHIBITING COMPOUNDS IN THE TREATMENT OF OBESITY AND THE LOWERING OF INSULIN LEVELS | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1987-09-30 | — | — | EP | claimed |
| US-4500540-A | DIETETICS | HOFFMANN-LA ROCHE INC. (US) | 1985-02-19 | — | — | US | claimed |
| EP-2739572-B1 | EXTRACTION OF METAL (IONS) BY MEANS OF IONIC LIQUIDS | UNIV DRESDEN TECH (DE) | 2017-03-01 | — | — | EP | disclosed |
| EP-2254871-B1 | SALTS COMPRISING ARYL-ALKYL-SUBSTITUTED IMIDAZOLIUM AND TRIAZOLIUM CATIONS AS IONIC FLUIDS | UNIV DRESDEN TECH (DE) | 2016-11-09 | — | — | EP | disclosed |
| EP-2254871-B1 | SALTS COMPRISING ARYL-ALKYL-SUBSTITUTED IMIDAZOLIUM AND TRIAZOLIUM CATIONS AS IONIC FLUIDS | UNIV DRESDEN TECH (DE) | 2016-11-09 | — | — | EP | disclosed |
| US-9260397-B2 | Salts comprising aryl-alkyl-substituted imidazolium and triazolium cations and the use thereof | TECHNISCHE UNIVERSITAET DRESDEN (DE) | 2016-02-16 | — | — | US | disclosed |
| US-9260397-B2 | Salts comprising aryl-alkyl-substituted imidazolium and triazolium cations and the use thereof | TECHNISCHE UNIVERSITAET DRESDEN (DE) | 2016-02-16 | — | — | US | disclosed |
| CN-104507473-A | Antiviral drug for treatment of arenavirus infection | SIGA TECHNOLOGIES INC | 2015-04-08 | — | — | CN | disclosed |
| EP-2814486-A2 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | Kineta Four LLC (US) | 2014-12-24 | — | — | EP | disclosed |
| WO-2013123215-A2 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES, INC. (US) | 2013-08-22 | — | — | WO | disclosed |
| US-8293715-B2 | 10a-Azalide compound crosslinked at 10a- and 12-positions | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-10-23 | — | — | US | disclosed |
| US-20110237784-A1 | 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| US-20110105761-A1 | Salts Comprising Aryl-Alkyl-Substituted Imidazolium and Triazolium Cations and the Use Thereof | TECHNISCHE UNIVERSITAET DRESDEN (DE) | 2011-05-05 | — | — | US | disclosed |
| US-20110105761-A1 | Salts Comprising Aryl-Alkyl-Substituted Imidazolium and Triazolium Cations and the Use Thereof | TECHNISCHE UNIVERSITAET DRESDEN (DE) | 2011-05-05 | — | — | US | disclosed |
| EP-2254871-A1 | SALTS COMPRISING ARYL-ALKYL-SUBSTITUTED IMIDAZOLIUM AND TRIAZOLIUM CATIONS AS IONIC FLUIDS | Technische Universität Dresden (DE) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009095012-A1 | SALTS COMPRISING ARYL-ALKYL-SUBSTITUTED IMIDAZOLIUM AND TRIAZOLIUM CATIONS AND THE USE THEREOF | Technische Universität Dresden (DE) | 2009-08-06 | — | — | WO | disclosed |
| WO-2009095012-A1 | SALTS COMPRISING ARYL-ALKYL-SUBSTITUTED IMIDAZOLIUM AND TRIAZOLIUM CATIONS AND THE USE THEREOF | Technische Universität Dresden (DE) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237784-A1 | 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS | DCLRE1A, AZI2, CHD9 | CYP2D6 2036/4885CYP2C9 122/4885CYP3A4 1260/4885 |
| US-20110105761-A1 | Salts Comprising Aryl-Alkyl-Substituted Imidazolium and Triazolium Cations and the Use Thereof | RDX, HAX1, CHRM2 | CYP2D6 685/4885CYP2C9 351/4885CYP3A4 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.